Bayer, Onyx file Nexavar in the US & EU for thyroid cancer
This article was originally published in Scrip
Executive Summary
Partners Bayer Healthcare and Onyx Pharmaceuticals have submitted applications to both the US FDA and the European Medicines Agency for the approval of Nexavar (sorafenib) tablets as a treatment for thyroid cancer patients who have run out of approved therapeutic options.